19:29 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hemophilia Cell culture and mouse studies suggest an engineered mutant Factor VIIa/Tissue Factor complex could help treat hemophilia A. The mutant complex consisted of Factor VIIa and soluble TF harboring Q64C and G109C mutations,...
07:00 , Jul 16, 2015 |  BC Innovations  |  Translation in Brief

Bayer's replacement antibody

Bayer AG 's new mAb could treat hemophilia patients who have neutralizing antibodies against coagulation factors, and avoid the frequent IV infusions of factor replacement therapy. In a departure from Bayer AG's historical focus on...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Factor Xa; thrombin (factor IIa; F2); factor IXa; factor VIIa/tissue factor complex In vitro studies suggest a combination of aptamers that inhibit coagulation...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

rNAPc2: Development halted

NUVO will discontinue an ongoing Phase II trial in colorectal cancer and suspend development of rNAPc2 for all indications, which include cancer and acute coronary syndrome. The company said it made the decision in order...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Clinical News

rNAPc2: Phase II data

NUVO published previously reported data in the Journal of American College of Cardiology from the Phase II ANTHEM/TIMI 32 study in 255 patients showing that higher doses of rNAPc2 reduced the incidence and duration of...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Clinical News

rNAPc2: Phase II started

NUVO began a placebo-controlled, dose-escalation Phase II trial of rNAPc2 in combination with 5-fluorouracil (5-FU) in 100 patients. Nuvelo Inc. (NUVO), San Carlos, Calif.   Product: rNAPc2   Business: Cancer   Molecular target: Factor VIIa/Tissue...
07:00 , Sep 11, 2006 |  BC Week In Review  |  Clinical News

rNAPc2: Phase IIa data

Data from the U.S. and Canadian Phase II ANTHEM/TIMI 32 study in 255 patients showed no significant increase in major/minor bleeding with rNAPc2 treatment vs. placebo (3.7% vs. 2.5%). The compound did produce dose-dependent increases...
07:00 , Sep 11, 2006 |  BC Week In Review  |  Clinical News

rNAPc2: Phase II data

Data from the U.S. and Canadian Phase II ANTHEM/TIMI 32 study in 255 patients showed no significant increase in major/minor bleeding with rNAPc2 treatment vs. placebo (3.7% vs. 2.5%). The compound did produce dose-dependent increases...
08:00 , Nov 21, 2005 |  BC Week In Review  |  Clinical News

rNAPc2: Phase IIa data

In the double-blind, dose-escalation, U.S. and Canadian Phase IIa ANTHEM/TIMI 32 trial in 203 patients, rNAPc2 inhibited thrombin generation without increasing bleeding. Major and minor bleed rate with rNAPc2 was 4.3% vs. 2.5% with placebo,...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Clinical News

rNAPc2: Phase IIb started

NUVO began the single-arm, open-label, U.S. and Canadian Phase IIb ANTHEM/TIMI 32b trial in 50-100 patients. The first cohort of 25 patients will receive a half-dose regimen of unfractionated heparin plus 10 mg/kg rNAPc2. The...